Baljendra Kapoor1, Anukul Panu, Bruce Berscheid. 1. Vascular and Interventional Radiology, The University of Alabama at Birmingham, Birmingham, Alabama 35249, USA. bkapoor@uabmc.edu
Abstract
PURPOSE: To assess the technical success and complications of Angio-Seal vascular closure device in antegrade common femoral artery (CFA) punctures. METHODS: Over a 14-month period, 55 patients (37 men; age range 37-94 years) underwent antegrade CFA Angio-Seal placement at a single center; the clinical data and angiograms were reviewed retrospectively. A total of 56 antegrade CFA punctures were made for hemostasis; 6-F Angio-Seal devices (40 model STS and 12 model VIP) were deployed in 52 CFAs, and 8-F Angio-Seal devices were deployed in 4. RESULTS: The technical success rate was 98.2% (55/56). Two (3.6%) patients developed small, non-expanding hematomas (<5 cm) during deployment of the device. There was 1 episode of device/operator failure, presumably due to extravascular deployment within soft tissue. None of the patients developed pseudoaneurysm, arterial injury, or large hematomas requiring transfusion. Small calcified plaques at the puncture site did not influence the outcome. CONCLUSION: This series suggests that Angio-Seal may be a safe and effective device for hemostasis in antegrade CFA punctures. Further randomized trials testing its risk-benefit balance in comparison to standard manual compression are warranted.
PURPOSE: To assess the technical success and complications of Angio-Seal vascular closure device in antegrade common femoral artery (CFA) punctures. METHODS: Over a 14-month period, 55 patients (37 men; age range 37-94 years) underwent antegrade CFA Angio-Seal placement at a single center; the clinical data and angiograms were reviewed retrospectively. A total of 56 antegrade CFA punctures were made for hemostasis; 6-F Angio-Seal devices (40 model STS and 12 model VIP) were deployed in 52 CFAs, and 8-F Angio-Seal devices were deployed in 4. RESULTS: The technical success rate was 98.2% (55/56). Two (3.6%) patients developed small, non-expanding hematomas (<5 cm) during deployment of the device. There was 1 episode of device/operator failure, presumably due to extravascular deployment within soft tissue. None of the patients developed pseudoaneurysm, arterial injury, or large hematomas requiring transfusion. Small calcified plaques at the puncture site did not influence the outcome. CONCLUSION: This series suggests that Angio-Seal may be a safe and effective device for hemostasis in antegrade CFA punctures. Further randomized trials testing its risk-benefit balance in comparison to standard manual compression are warranted.